
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Alix CRISPR/Cas9 KO Plasmid (m) | sc-422154 | 20 µg | $397.00 |
Pdcd6ip encodes ALIX, a multifunctional adaptor that couples membrane remodeling to endosomal trafficking through interactions with ESCRT components, including CHMP4 proteins, and partners such as TSG101. In mouse cells, ALIX contributes to multivesicular body biogenesis, exosome release, cytokinetic abscission, and plasma membrane repair, and it can influence apoptosis-linked signaling through its binding networks. ALIX-dependent ESCRT activity is also co-opted during budding of enveloped viruses and regulates turnover of membrane receptors, linking Pdcd6ip to pathways controlling cell signaling and proteostasis. Dysregulation of ESCRT/ALIX-mediated trafficking has been associated with neurodegeneration, tumor biology, and immune and viral pathogenesis in experimental systems, making Pdcd6ip a useful node for mechanistic studies of membrane dynamics.
Alix CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Pdcd6ip gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Pdcd6ip together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Pdcd6ip open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Alix protein expression.
This CRISPR knockout system enables efficient generation of Pdcd6ip-deficient cell models for investigation of Alix signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.